Registry for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to gather information on patients with plasma cell disorders (PCDs), such as multiple myeloma, using a geriatric assessment, which is a comprehensive evaluation of an older adult's health and functional status. The study will examine patient responses to the assessment and their satisfaction with it. An optional blood test will check a genetic marker related to aging. Patients diagnosed with a PCD, receiving care at UNC Cancer Hospitals or affiliated sites, and able to complete the assessment may be suitable for this trial. As an unphased trial, this study offers patients the chance to contribute to research that could enhance care for older adults with PCDs.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It would be best to discuss this with the study team or your doctor.
What prior data suggests that this protocol is safe for patients with plasma cell disorders?
Research has shown that geriatric assessments are generally safe. These assessments evaluate physical health, mental well-being, and social support. Being non-invasive, they do not involve surgery or entering the body, so most individuals tolerate them well. No reports of serious side effects have emerged from these assessments.
Prospective participants in a study involving a geriatric assessment can feel confident about its safety. The process resembles a detailed health check-up and helps doctors understand how various factors affect aging and health.
Why are researchers excited about this trial?
Researchers are excited about using geriatric assessment for plasma cell disorders (PCDs) because it focuses on understanding the broader health needs of older adults with these conditions, rather than just the disease itself. Unlike traditional treatments that primarily target the cancer cells, a geriatric assessment evaluates a patient's overall health, including physical function, mental health, and social support, to tailor a more personalized treatment plan. This approach can potentially improve the quality of life and treatment outcomes for older patients with PCDs, who often face unique challenges due to age-related factors.
What evidence suggests that this geriatric assessment is effective for patients with plasma cell disorders?
Research has shown that thorough health check-ups for older adults, known as comprehensive geriatric assessments (CGA), can lead to better health outcomes. One study found that CGA improved memory and thinking skills in patients three months after the check-up. Another study demonstrated that CGA lowered death rates for frail older patients six months later. Additionally, CGA helps doctors identify issues like memory problems and depression, leading to better care. These findings suggest that CGA could benefit people with plasma cell disorders, potentially enhancing their overall health and well-being.12345
Who Is on the Research Team?
Sascha Tuchman, MD
Principal Investigator
UNC Lineberger Comprehensive Cancer Center
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants complete a multi-dimensional inter-disciplinary evaluation of functional status, co-morbid conditions, cognition, psychological status, social functioning, medication review, and nutritional status
Longitudinal Assessment
Participants repeat the assessment longitudinally over time to monitor changes in functional status and other health parameters
Follow-up
Participants are monitored for safety and effectiveness after assessments
What Are the Treatments Tested in This Trial?
Interventions
- Geriatric Assessment
Find a Clinic Near You
Who Is Running the Clinical Trial?
UNC Lineberger Comprehensive Cancer Center
Lead Sponsor